Showing results (101-110 of 118) with videos related to
Sort By:
Pageof 12
Haematologica|March 13, 2025
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow upAndrew J Portuguese, Jennifer J Huang, Yein Jeon, et al.Medrxiv : the Preprint Server for Health Sciences|January 7, 2025
Acute Myeloid Leukemia Skews Therapeutic WT1-specific CD8 TCR-T Cells Towards an NK-like Phenotype that Compromises Function and PersistenceFrancesco Mazziotta, Lauren E Martin, Daniel N Eagan, et al.Medrxiv : the Preprint Server for Health Sciences|July 15, 2024
Tumor Regression Following Engineered Polyomavirus-Specific T Cell Therapy in Immune Checkpoint Inhibitor-Refractory Merkel Cell CarcinomaYuta Asano, Joshua Veatch, Megan McAfee, et al.Transplantation and Cellular Therapy|February 28, 2026
Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory HurdlesKedar Kirtane, Michael Kalos, Rocky Billups, et al.Nature Communications|September 26, 2018
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLAK G Paulson, V Voillet, M S McAfee, et al.Nature Communications|June 5, 2025
A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistenceFrancesco Mazziotta, Lauren E Martin, Daniel N Egan, et al.Nature Medicine|June 26, 2019
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplantAude G Chapuis, Daniel N Egan, Merav Bar, et al.Blood Advances|October 30, 2023
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphomaAlexandre V Hirayama, Erik L Kimble, Jocelyn H Wright, et al.Research Square|October 20, 2022
CD8+ T cell clonotypes from prior SARS-CoV-2 infection predominate during the cellular immune response to mRNA vaccinationEmily S Ford, Koshlan Mayer-Blackwell, Lichen Jing, et al.Blood|February 8, 2019
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapyKevin A Hay, Jordan Gauthier, Alexandre V Hirayama, et al.Pageof 12